EUVIMEDEUVIMED entdecken
Crossref

Enhancing COVID-19 Vaccine Efficacy: Dual Adjuvant Strategies with TLR7/8 Agonists and Glycolipids

Ke Li, Xing Hu, Xin-Yi Tu, Mao-Ying Xian, Lei-Lei Huang, Ting Huang, Rui Luo, Hui Jin, Zheng Liu iD

Journal of Medicinal Chemistry · 2024

DOI: 10.1021/acs.jmedchem.4c01801 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Ke Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, Hubei, P. R. China. Hauptthemen laut MEDLINE: Toll-Like Receptor 8, Toll-Like Receptor 7, COVID-19 Vaccines, Adjuvants, Immunologic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Higher Education Discipline Innovation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The controlled release of immunostimulatory agents represents a promising strategy to enhance vaccine efficacy while minimizing side effects. This study aimed to improve the efficacy of the RBD-Fc-based COVID-19 vaccine through combining of an iNKT cell agonist and a TLR7/8 agonist using covalent conjugation and temporal delivery. We hypothesized that these combinations would yield a more balanced Th1/Th2 immune response. For covalent conjugation, we employed an uncleavable linker and a self-immolative disulfide linker to conjugate α-galactosylceramide (αGC) to imidazoquinoline (IMDQ). The αGC-SS-IMDQ-Ac conjugate, designed with a prodrug strategy for controlled TLR7/8 agonist release, elicited a higher IFN-γ/IL-4 T cell response ratio than individual adjuvants or their admixture. In the temporal delivery approach, administering IMDQ followed by αGC after 2 h resulted in the highest IgG2a/IgG1 ratio, significantly surpassing other groups. A 6 h delay between glycolipid and IMDQ injections yielded balanced IgG responses, enhancing IgG, IgG1, and IgG2a levels synergistically.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 8Toll-Like Receptor 7COVID-19 VaccinesAdjuvants, ImmunologicGalactosylceramidesAnimalsMiceGlycolipidsHumansSARS-CoV-2FemaleNatural Killer T-CellsCOVID-19QuinolinesImidazolesImmunoglobulin G

Substanzen

Toll-Like Receptor 8Toll-Like Receptor 7COVID-19 VaccinesAdjuvants, ImmunologicGalactosylceramidesalpha-galactosylceramideGlycolipidsQuinolinesImidazolesImmunoglobulin G

Autor:innen und Institutionen

  • State Key Laboratory of Agricultural Microbiology, College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, Hubei, P. R. China.
  • National Key Laboratory of Green Pesticide, Hubei International Scientific and Technological Cooperation Base of Pesticide and Green Synthesis, International Joint Research Center for Intelligent Biosensing Technology a…

ORCID-Profile: Zheng Liu

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Higher Education Discipline Innovation Project

Zitieren

APA

Li, K., Hu, X., Tu, X. Y., Xian, M. Y., Huang, L. L., Huang, T., Luo, R., Jin, H., & Liu, Z. (2024). Enhancing COVID-19 Vaccine Efficacy: Dual Adjuvant Strategies with TLR7/8 Agonists and Glycolipids. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01801

Vancouver

Li K, Hu X, Tu XY, Xian MY, Huang LL, Huang T, et al. Enhancing COVID-19 Vaccine Efficacy: Dual Adjuvant Strategies with TLR7/8 Agonists and Glycolipids. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c01801

BibTeX
@article{Li2024,
  author = {Li, Ke and Hu, Xing and Tu, Xin-Yi and Xian, Mao-Ying and Huang, Lei-Lei and Huang, Ting and Luo, Rui and Jin, Hui and Liu, Zheng},
  title = {Enhancing COVID-19 Vaccine Efficacy: Dual Adjuvant Strategies with TLR7/8 Agonists and Glycolipids},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  doi = {10.1021/acs.jmedchem.4c01801}
}
Kostenlos starten →